151 related articles for article (PubMed ID: 21812736)
1. Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension.
Yoshida S; Shirato K; Shimamura R; Nakahara N; Iwase T; Nakajima H
Curr Med Res Opin; 2011 Sep; 27(9):1827-34. PubMed ID: 21812736
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension.
Yoshida S; Shirato K; Shimamura R; Iwase T; Aoyagi N; Nakajima H
Curr Med Res Opin; 2012 Jun; 28(6):1069-76. PubMed ID: 22506623
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
[TBL] [Abstract][Full Text] [Related]
4. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
Galiè N; Olschewski H; Oudiz RJ; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Gerber MJ; Dufton C; Wiens BL; Rubin LJ;
Circulation; 2008 Jun; 117(23):3010-9. PubMed ID: 18506008
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
Ivy D; Beghetti M; Juaneda-Simian E; Ravindranath R; Lukas MA; Machlitt-Northen S; Scott N; Narita J; Berger RMF
Eur J Pediatr; 2024 May; 183(5):2141-2153. PubMed ID: 38366267
[TBL] [Abstract][Full Text] [Related]
6. Ambrisentan therapy for pulmonary arterial hypertension.
Galié N; Badesch D; Oudiz R; Simonneau G; McGoon MD; Keogh AM; Frost AE; Zwicke D; Naeije R; Shapiro S; Olschewski H; Rubin LJ
J Am Coll Cardiol; 2005 Aug; 46(3):529-35. PubMed ID: 16053970
[TBL] [Abstract][Full Text] [Related]
7. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
[TBL] [Abstract][Full Text] [Related]
8. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.
Takatsuki S; Rosenzweig EB; Zuckerman W; Brady D; Calderbank M; Ivy DD
Pediatr Pulmonol; 2013 Jan; 48(1):27-34. PubMed ID: 22511577
[TBL] [Abstract][Full Text] [Related]
9. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan.
Shapiro S; Pollock DM; Gillies H; Henig N; Allard M; Blair C; Anglen C; Kohan DE
Am J Cardiol; 2012 Nov; 110(9):1373-7. PubMed ID: 22858181
[TBL] [Abstract][Full Text] [Related]
10. Ambrisentan.
Croxtall JD; Keam SJ
Drugs; 2008; 68(15):2195-204. PubMed ID: 18840007
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
Li M; Jing ZC; Li Y; Huo Y; Yu Z; Zhang G; Zhu P; Liu J; Ji Q; Wu B; Zhong J; Wang P; Zhu W; Zeng X
BMC Cardiovasc Disord; 2020 Jul; 20(1):339. PubMed ID: 32680480
[TBL] [Abstract][Full Text] [Related]
12. Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study.
Harrison B; Magee MH; Mandagere A; Walker G; Dufton C; Henderson LS; Boinpally R
Clin Drug Investig; 2010; 30(12):875-885. PubMed ID: 20923245
[TBL] [Abstract][Full Text] [Related]
13. Ambrisentan: a review of its use in pulmonary arterial hypertension.
Rivera-Lebron BN; Risbano MG
Ther Adv Respir Dis; 2017 Jun; 11(6):233-244. PubMed ID: 28425346
[TBL] [Abstract][Full Text] [Related]
14. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.
Safdar Z
Vasc Health Risk Manag; 2011; 7():119-24. PubMed ID: 21468170
[TBL] [Abstract][Full Text] [Related]
15. Role of ambrisentan in the management of pulmonary hypertension.
Hrometz SL; Shields KM
Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
[TBL] [Abstract][Full Text] [Related]
16. Ambrisentan for the management of pulmonary arterial hypertension.
Cheng JW
Clin Ther; 2008 May; 30(5):825-33. PubMed ID: 18555930
[TBL] [Abstract][Full Text] [Related]
17. Ambrisentan.
Frampton JE
Am J Cardiovasc Drugs; 2011 Aug; 11(4):215-26. PubMed ID: 21623643
[TBL] [Abstract][Full Text] [Related]
18. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.
Badesch DB; Feldman J; Keogh A; Mathier MA; Oudiz RJ; Shapiro S; Farber HW; McGoon M; Frost A; Allard M; Despain D; Dufton C; Rubin LJ;
Cardiovasc Ther; 2012 Apr; 30(2):93-9. PubMed ID: 21884013
[TBL] [Abstract][Full Text] [Related]
19. Bioequivalence and Tolerability of Ambrisentan: A Pharmacokinetic Study in Mexican Healthy Male Subjects.
Cárdenas KPC; Velázquez JER; Escobar JJO; Chirinos J; Pendela M
Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):611-618. PubMed ID: 32472357
[TBL] [Abstract][Full Text] [Related]
20. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
Oudiz RJ; Galiè N; Olschewski H; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Harrison BC; Despain D; Dufton C; Rubin LJ;
J Am Coll Cardiol; 2009 Nov; 54(21):1971-81. PubMed ID: 19909879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
